Pauline Pradère, Igor Tudorache, Jesper Magnusson, Laurent Savale, Olivier Brugiere, Benoît Douvry, Martine Reynaud-Gaubert, Johanna Claustre, Aurélie Le Borgne, Are M Holm, Hans Henrik Schultz, Christiane Knoop, Laurent Godinas, Andrew J Fisher, Sandrine Hirschi, Jens Gottlieb, Jérôme Le Pavec
BACKGROUND: Due to its multisystemic nature, scleroderma is considered a relative contraindication to lung transplantation at many centers. However, recent studies suggest similar post-transplant outcomes in patients with scleroderma compared to those with other causes of interstitial lung disease (ILD). Furthermore, it remains unknown whether scleroderma-associated pulmonary arterial hypertension (PAH) influences post-transplant outcomes. Our objective in this study was to assess the indications, survival, and prognostic factors of lung or heart-lung transplantation for scleroderma lung disease...
March 15, 2018: Journal of Heart and Lung Transplantation